巴姆兰尼单抗与安慰剂对养老院和辅助生活机构居民及员工COVID-19发病率的影响:一项随机临床试验
这项随机双盲3期试验在74家美国养老院和辅助生活机构中,对1175名居民和员工单次静脉输注巴姆兰尼单抗4200 mg或安慰剂。在966名基线SARS-CoV-2阴性参与者中,巴姆兰尼单抗组8周内COVID-19发病率为8.5%,显著低于安慰剂组的15.2%(OR 0.43,95%CI 0.28-0.68;P<.001)。
要点
- 巴姆兰尼单抗单次静脉输注可降低养老机构居民和员工COVID-19发病率。
- 预防人群中COVID-19发病率8.5% vs 15.2%,绝对风险差-6.6个百分点。
- 至第57天5例COVID-19相关死亡均发生于安慰剂组。
核心结论
- 在养老院和辅助生活机构居民及员工中,巴姆兰尼单抗单药治疗可降低COVID-19发病率。
- 需进一步研究评估针对当前病毒株流行模式的预防效力及联合单克隆抗体疗法。
研究设计与样本
- 随机、双盲、单剂量、3期试验,纳入美国74家养老院和辅助生活机构的居民及员工。
- 2020年8月2日至11月20日共入组1175名参与者,随机接受巴姆兰尼单抗4200 mg(n=588)或安慰剂(n=587)单次静脉输注。
- 预防人群共966名基线SARS-CoV-2感染和血清学阴性参与者(666名员工和300名居民;平均年龄53.0岁,范围18-104岁;722名女性,占74.7%)。
主要发现
- 预防人群中,巴姆兰尼单抗组COVID-19发病率为8.5%,安慰剂组为15.2%(OR 0.43,95%CI 0.28-0.68;P<.001;绝对风险差-6.6个百分点,95%CI -10.7至-2.6)。
- 至第57天报告5例COVID-19相关死亡,均发生于安慰剂组。
- 安全性人群中,巴姆兰尼单抗组不良事件发生率为20.1%,安慰剂组为18.9%。
- 最常见不良事件为尿路感染(巴姆兰尼单抗组12例[2%],安慰剂组14例[2.4%])和高血压(巴姆兰尼单抗组7例[1.2%],安慰剂组10例[1.7%])。
关键数值与推荐
- 主要结局为随机化后8周内、检测到SARS-CoV-2后21天内出现轻度或更严重疾病严重程度的COVID-19发病率。
- 关键次要结局包括中度或更严重COVID-19严重程度发病率及SARS-CoV-2感染发病率。
临床怎么用
- 在养老院和辅助生活机构疫情暴发期间,可考虑对居民和员工使用巴姆兰尼单抗单次静脉输注以降低COVID-19发病率。
- 应用时需注意研究期间为2020年8月至11月,当前病毒株流行模式可能影响预防效力。
局限性
- 研究期间为2020年8月至11月,结论需在当前病毒株流行模式下进一步验证。
- 需进一步研究评估联合单克隆抗体疗法的预防效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19. OBJECTIVE: To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, single-dose, phase 3 trial that enrolled residents and staff of 74 skilled nursing and assisted living facilities in the United States with at least 1 confirmed SARS-CoV-2 index case. A total of 1175 participants enrolled in the study from August 2 to November 20, 2020. Database lock was triggered on January 13, 2021, when all participants reached study day 57. INTERVENTIONS: Participants were randomized to receive a single intravenous infusion of bamlanivimab, 4200 mg (n = 588), or placebo (n = 587). MAIN OUTCOMES AND MEASURES: The primary outcome was incidence of COVID-19, defined as the detection of SARS-CoV-2 by reverse transcriptase-polymerase chain reaction and mild or worse disease severity within 21 days of detection, within 8 weeks of randomization. Key secondary outcomes included incidence of moderate or worse COVID-19 severity and incidence of SARS-CoV-2 infection. RESULTS: The prevention population comprised a total of 966 participants (666 staff and 300 residents) who were negative at baseline for SARS-CoV-2 infection and serology (mean age, 53.0 [range, 18-104] years; 722 [74.7%] women). Bamlanivimab significantly reduced the incidence of COVID-19 in the prevention population compared with placebo (8.5% vs 15.2%; odds ratio, 0.43 [95% CI, 0.28-0.68]; P < .001; absolute risk difference, -6.6 [95% CI, -10.7 to -2.6] percentage points). Five deaths attributed to COVID-19 were reported by day 57; all occurred in the placebo group. Among 1175 participants who received study product (safety population), the rate of participants with adverse events was 20.1% in the bamlanivimab group and 18.9% in the placebo group. The most common adverse events were urinary tract infection (reported by 12 participants [2%] who received bamlanivimab and 14 [2.4%] who received placebo) and hypertension (reported by 7 participants [1.2%] who received bamlanivimab and 10 [1.7%] who received placebo). CONCLUSIONS AND RELEVANCE: Among residents and staff in skilled nursing and assisted living facilities, treatment during August-November 2020 with bamlanivimab monotherapy reduced the incidence of COVID-19 infection. Further research is needed to assess preventive efficacy with current patterns of viral strains with combination monoclonal antibody therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04497987.
引用
- Cohen MS, Nirula A, Mulligan MJ, et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA. 2021. PMID: 34081073. doi:10.1001/jama.2021.8828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。